FOLD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amicus Therapeutics Inc (FOLD) is not a strong buy for a long-term beginner investor at this time. While the stock shows some bullish moving averages and stable technical indicators, the lack of significant positive catalysts, weak financial performance in the latest quarter, and neutral trading sentiment suggest that this is not an ideal entry point. Additionally, the absence of recent AI Stock Picker or SwingMax signals further reduces the attractiveness of this stock for immediate investment.
The technical indicators show mixed signals. While the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is below zero and negatively contracting, and the RSI is neutral at 58.228. Key support and resistance levels are close to the current price, indicating limited immediate upside potential.
NULL identified. There are no recent news events, significant insider or hedge fund activity, or congress trading data to act as positive catalysts.
Weak financial performance in 2025/Q4, with net income dropping by -88.53% YoY and EPS falling by -80.00% YoY. Gross margin also declined by -4.61% YoY. Additionally, stock trend analysis suggests a potential decline of -4.61% in the next week and -13.55% in the next month.
In 2025/Q4, revenue increased by 23.72% YoY to $185.21M, but net income dropped significantly by -88.53% YoY to $1.69M. EPS also fell by -80.00% YoY to $0.01, and gross margin declined by -4.61% YoY to 84.64%. The financial performance indicates growth in revenue but significant profitability challenges.
No recent analyst rating or price target updates are provided for this stock.
